Compare UBFO & NVCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UBFO | NVCT |
|---|---|---|
| Founded | 1987 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 177.0M | 193.4M |
| IPO Year | N/A | 2022 |
| Metric | UBFO | NVCT |
|---|---|---|
| Price | $10.03 | $8.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $15.33 |
| AVG Volume (30 Days) | 61.0K | ★ 92.5K |
| Earning Date | 01-26-2026 | 02-24-2026 |
| Dividend Yield | ★ 4.72% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.65 | N/A |
| Revenue | ★ $46,495,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.63 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.32 | $5.34 |
| 52 Week High | $10.53 | $11.52 |
| Indicator | UBFO | NVCT |
|---|---|---|
| Relative Strength Index (RSI) | 49.66 | 60.39 |
| Support Level | $9.96 | $8.00 |
| Resistance Level | $10.21 | $9.44 |
| Average True Range (ATR) | 0.18 | 0.52 |
| MACD | -0.04 | 0.04 |
| Stochastic Oscillator | 34.85 | 53.15 |
United Security Bancshares operates as the holding for United Security Bank. It provides commercial banking services to the business and professional community, and individuals located in Fresno, Madera, Santa Clara, and Kern Counties. It offers checking and savings accounts, deposits, mortgage loans, credit and debit cards, safe deposit boxes, automated teller machines, wire transfers, money market accounts, mobile banking, and wealth management services. The company's primary sources of revenue are interest income from loans and investment securities.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.